Condition: Advanced Solid Tumor · Mesothelioma, Malignant · Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.
This description comes directly from the study's public registry record.
US Medical Information · 888-275-7376 · eMediUSA@emdserono.com
Always discuss trial participation with your own doctor first.
| HonorHealth Research Institute | Scottsdale, Arizona, United States | Recruiting |
| USC Norris Comprehensive Cancer Center and Hospital | Los Angeles, California, United States | Recruiting |
| UC San Diego Moores Cancer Center | Sacramento, California, United States | Recruiting |
| UCLA Hematology-Oncology - Santa Monica | Santa Monica, California, United States | Recruiting |
| University Hospital of Cleveland | Cleveland, Ohio, United States | Recruiting |
| Oregon Health and Science University, Knight Cancer Institute - Marquam Hill | Portland, Oregon, United States | Recruiting |
| Mary Crowley Research Center US Oncology | Dallas, Texas, United States | Recruiting |
| U.T. MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06251310